发明名称 Hepatitis C virus inhibitors
摘要 The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:; which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with the compounds.
申请公布号 US8815928(B2) 申请公布日期 2014.08.26
申请号 US201012879028 申请日期 2010.09.10
申请人 Enanta Pharmaceuticals, Inc. 发明人 Or Yat Sun;Ying Lu;Peng Xiaowen;Wang Ce;Qiu Yao-Ling
分类号 A61K31/4178;C07D403/10 主分类号 A61K31/4178
代理机构 Elmore Patent Law Group, P.C. 代理人 Issac, Esq. Roy P.;Elmore, Esq. Carolyn S.;Elmore Patent Law Group, P.C.
主权项 1. A compound selected from compounds compiled in the following table or a pharmaceutically acceptable salt thereof:Entry3131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960646577808586879293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181184196200201202203204205206207208210211212213214215216217218219 .
地址 Watertown MA US